ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
Probiotic-Enhanced Porous Bio-Hybrids with Inflammatory Targeting, ROS Scavenging, and Long-Term Drug Release for Ulcerative Colitis Treatment.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Curcumin-loaded tetrahedral framework nucleic acids reshape intestinal homeostasis in ulcerative colitis by coordinating barrier repair, microbiota reconstruction, and immune modulation.Materials today. Bio · 2026Article
- Reprogramming the gastrointestinal microenvironment with intelligent biomaterials and digital medicine: a perspective on precision intervention for digestive diseases.Frontiers in bioengineering and biotechnology · 2026Article
- Under-Urine-Adhered Supramolecular Hydrogel with Linearly Sustained Quercetin Release Facilitates Hemorrhagic Cystitis Healing via Inflammation Regulation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Targeted expression of the immunomodulatory peptide Scy by engineeredFrontiers in immunology · 2026Article
- Probiotic-Enhanced Porous Bio-Hybrids with Inflammatory Targeting, ROS Scavenging, and Long-Term Drug Release for Ulcerative Colitis Treatment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Anti-inflammatory effects of natural polysaccharides: molecular mechanisms and nanotherapeutic applications.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Functional porous materials hold significant promise for biomedical applications owing to their high surface area and customizable pore architectures. However, the complex gastrointestinal environment poses considerable challenges for conventional nanomaterials in achieving targeted accumulation and controlled drug release. Herein, a kind of novel probiotic-enhanced porous bio-hybrids (E-xPAM@ASA) is designed via bio-hybridization of 5-aminosalicylic acid-loaded hairy microporous nanospheres (xPAM@ASA) with probiotic Escherichia coli Nissle 1917. Benefiting from the intrinsic inflammatory-targeting capability of EcN, the E-xPAM@ASA can accumulate in the inflammatory sites of the intestine. The unique porous architecture of xPAM@ASA not only facilitates high drug loading and long-term release but also provides abundant adsorption sites for effective reactive oxygen species scavenging. In a dextran sulfate sodium-induced ulcerative colitis murine model, E-xPAM@ASA demonstrate superior therapeutic outcomes, including mucosal repair, inflammation alleviation, and microbiota regulation. These findings highlight the potential of the multifunctional nanocomposite as a precise therapeutic platform for the treatment of intestinal inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.